Monte Rosa Therapeutics, Inc. GLUE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -43.8%— | —— | —— | —— | |
| Net margin | -31.2%— | —— | —— | —— | |
| EBITDA margin | -37.1%— | —— | —— | —— | |
| Free cash flow margin | -22.2%-72.5pp | 50.3%— | —— | —— | |
| Returns | |||||
| Return on equity | -16.9%— | —— | -60.1%-25.0pp | -35.1%— | |
| Return on assets | -8.7%— | —— | -41.9%-11.3pp | -30.6%+5.0pp | |
| Return on invested capital | -59%— | —— | -79.5%+3.1pp | -82.5%— | |
| Efficiency | |||||
| Asset turnover | 0.3×+0.1× | 0.2×— | 0×— | —— | |
| Liquidity | |||||
| Current ratio | 6.1×+3.7× | 2.4×-2.7× | 5.1×-5.7× | 10.8×-10.2× | |
| Quick ratio | 6.1×+3.7× | 2.4×-2.7× | 5.1×-5.7× | 10.8×-10.2× | |
| Cash ratio | 2×+0.6× | 1.4×-1.3× | 2.7×+0.6× | 2.1×-18.7× | |
| Leverage | |||||
| Debt-to-equity | 0.2×0.0× | 0.2×-0.1× | 0.3×+0.1× | 0.2×+0.2× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | 0.2×0.0× | 0.1×+0.1× | |
| Interest coverage | -4.2×— | —— | -15.4×+14.5× | -29.9×+1,555× | |
| Per Share | |||||
| Book value per share | $2.81-7.0% | $3.02-13.5% | $3.49-39.3% | $5.75-58.7% | |
| Valuation | |||||
| Market capitalization | $1.02B+139% | $426.37M+32.6% | $321.64M-13.6% | $372.08M-60.9% | |
| Enterprise value | $930.35M+280% | $244.83M+2.2% | $239.58M-34.2% | $364.17M-40.6% | |
| Price / sales | 8.3×+2.6× | 5.6×— | —— | —— | |
| Price / book | 4.4×+2.5× | 1.9×+0.1× | 1.8×+0.4× | 1.4×-1.4× | |
| EV / sales | 7.5×+4.3× | 3.2×— | —— | —— | |
| Free cash flow yield | -2.7%-11.6pp | 8.9%— | —— | -28.3%-21.1pp | |
| Earnings yield | -3.8%— | —— | -42.1%-12.9pp | -29.2%-21.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Monte Rosa Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.